Flavopiridol was also shown to synergistically enhance the anti-myeloma effect of Bcl-2 antagonists, bortezomib and TRAIL, while seliciclib potentiates the anti-myeloma activity of doxorubicin and bortezomib [88, 90–92]. Here, BCL2 is linked to plasma cell myeloma.